{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:19:09Z","timestamp":1784740749822,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T00:00:00Z","timestamp":1652486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The management of patients with advanced\/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen. However, it is quite toxic, so an adequate supportive therapy is crucial to reduce as much as possible the side effects and maintain the dose intensity of cytotoxic agents.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We describe the main side effects of the EDP-M scheme and the best way to manage them based on the experience of the Medical Oncology Unit of the Spedali Civili of Brescia. We also deal with the administration of EDP-M in specific frail patients, such as those with huge disease extent and poor performance status (PS) and those with mild renal insufficiency.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In patients with hormone secreting ACC the rapid control of Cushing syndrome using adrenal steroidogenesis inhibitors such as metyrapone or osilodrostat is mandatory before starting EDP-M. Primary prophylaxis of neutropenia with Granulocyte-Colony Stimulating Factors is crucial and should be introduced at the first chemotherapy cycle. Possible mitotane induced hypoadrenalism should be always considered in case of persistent nausea and vomiting and asthenia in the interval between one cycle to another. In case of poor PS. A 24\u2009h continuous infusion schedule of cisplatin could be an initial option in patients with poor PS as well as to reduce the risk of nefrotoxocity in patients with mild renal impairment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A careful and accurate supportive care is essential to mitigate EDP-M side effects as much as possible and avoid that, due to toxicity, patients have to reduce doses and or postpone cytotoxic treatment with a negative impact on efficacy of this chemotherapy regimen.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-022-03075-y","type":"journal-article","created":{"date-parts":[[2022,5,14]],"date-time":"2022-05-14T13:03:28Z","timestamp":1652533408000},"page":"438-443","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen"],"prefix":"10.1007","volume":"77","author":[{"given":"Antonella","family":"Turla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Domenico","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Cremaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2952-9560","authenticated-orcid":false,"given":"Alfredo","family":"Berruti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,14]]},"reference":[{"issue":"4","key":"3075_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"M. Fassnacht, O.M. Dekkers, T. Else, E. Baudin, A. Berruti, R. de Krijger, H.R. Haak, R. Mihai, G. Assie, M. Terzolo, European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179(4), G1\u2013G46 (2018). https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"3075_CR2","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"M. Fassnacht, G. Assie, E. Baudin, G. Eisenhofer, C. de la Fouchardiere, H.R. Haak, R. de Krijger, F. Porpiglia, M. Terzolo, A. Berruti, ESMO Guidelines Committee: Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11), 1476\u20131490 (2020). https:\/\/doi.org\/10.1016\/j.annonc.2020.08.2099","journal-title":"Ann Oncol"},{"issue":"3","key":"3075_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1677\/erc.1.01025","volume":"12","author":"A Berruti","year":"2005","unstructured":"A. Berruti, M. Terzolo, P. Sperone, A. Pia, S. Della Casa, D.J. Gross, C. Carnaghi, P. Casali, F. Porpiglia, F. Mantero, G. Reimondo, A. Angeli, L. Dogliotti, Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective Phase II trial. Endocr Relat Cancer 12(3), 657\u2013666 (2005). https:\/\/doi.org\/10.1677\/erc.1.01025","journal-title":"Endocr Relat Cancer"},{"key":"3075_CR4","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366, 2189\u20132197 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N Engl J Med"},{"issue":"6","key":"3075_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1530\/EJE-19-0570","volume":"181","author":"D Cosentini","year":"2019","unstructured":"D. Cosentini, G. Badalamenti, S. Grisanti, V. Basile, I. Rapa, S. Cerri, A. Spallanzani, P. Perotti, E. Musso, M. Lagan\u00e0, V.D. Ferrari, G. Luppi, A. Dalla Volta, L. Incorvaia, S. Sigala, A. Russo, M. Volante, M. Terzolo, A. Berruti, Activity and safety of temozolomide in advanced adrenocortical carcinoma patients. Eur J Endocrinol 181(6), 681\u2013689 (2019). https:\/\/doi.org\/10.1530\/EJE-19-0570","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"3075_CR6","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1210\/jc.2017-01624","volume":"102","author":"JEK Henning","year":"2017","unstructured":"J.E.K. Henning, T. Deutschbein, B. Altieri, S. Steinhauer, S. Kircher, S. Sbiera, V. Wild, W. Schl\u00f6telburg, M. Kroiss, P. Perotti, A. Rosenwald, A. Berruti, M. Fassnacht, C.L. Ronchi, Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J Clin Endocrinol Metab 102(11), 4323\u20134332 (2017). https:\/\/doi.org\/10.1210\/jc.2017-01624","journal-title":"J Clin Endocrinol Metab"},{"key":"3075_CR7","doi-asserted-by":"publisher","first-page":"624102","DOI":"10.3389\/fendo.2021.624102","volume":"12","author":"S Grisanti","year":"2021","unstructured":"S. Grisanti, D. Cosentini, M. Lagan\u00e0, A. Morandi, B. Lazzari, L. Ferrari, A.D. Volta, R. Ambrosini, V.D. Ferrari, S. Sigala, A. Berruti, Clinical prognostic factors in patients with metastatic adrenocortical carcinoma treated with second line gemcitabine plus capecitabine chemotherapy. Front Endocrinol 12, 624102 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.624102","journal-title":"Front Endocrinol"},{"issue":"2","key":"3075_CR8","doi-asserted-by":"publisher","first-page":"100422","DOI":"10.1016\/j.esmoop.2022.100422","volume":"7","author":"M Lagan\u00e0","year":"2022","unstructured":"M. Lagan\u00e0, S. Grisanti, R. Ambrosini, D. Cosentini, A. Abate, M. Zamparini, V.D. Ferrari, A. Gianoncelli, A. Turla, L. Canu, M. Terzolo, G.A.M. Tiberio, S. Sigala, A. Berruti, Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ESMO Open 7(2), 100422 (2022). https:\/\/doi.org\/10.1016\/j.esmoop.2022.100422","journal-title":"ESMO Open"},{"key":"3075_CR9","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.coemr.2019.07.007","volume":"8","author":"S Grisanti","year":"2019","unstructured":"S. Grisanti, D. Cosentini, M. Lagan\u00e0 et al. Are we failing in treatment of adrenocortical carcinoma? Lights and shadows of molecular signatures. Curr Opin Endocr Metab Res 8, 80\u201387 (2019)","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"2019","key":"3075_CR10","doi-asserted-by":"publisher","first-page":"6072863","DOI":"10.1155\/2019\/6072863","volume":"1","author":"C Fiorentini","year":"2019","unstructured":"C. Fiorentini, S. Grisanti, D. Cosentini, A. Abate, E. Rossini, A. Berruti, S. Sigala, Molecular drivers of potential immunotherapy failure in adrenocortical carcinoma. J Oncol 1(2019), 6072863 (2019). https:\/\/doi.org\/10.1155\/2019\/6072863","journal-title":"J Oncol"},{"issue":"36","key":"3075_CR11","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.2217\/fon-2020-0686","volume":"16","author":"S Grisanti","year":"2020","unstructured":"S. Grisanti, D. Cosentini, M. Lagan\u00e0, A.D. Volta, C. Palumbo, T.G.A. Massimo, S. Sigala, A. Berruti, The long and winding road to effective immunotherapy in patients with adrenocortical carcinoma. Future Oncol 16(36), 3017\u20133020 (2020). https:\/\/doi.org\/10.2217\/fon-2020-0686","journal-title":"Future Oncol"},{"issue":"1","key":"3075_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"G.H. Lyman, Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 7(1), 99\u2013108 (2009). https:\/\/doi.org\/10.6004\/jnccn.2009.0009","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"3075_CR13","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","volume":"4","author":"R Pivonello","year":"2016","unstructured":"R. Pivonello, A.M. Isidori, M.C. De Martino, J. Newell-Price, B.M. Biller, A. Colao, Complications of Cushing\u2019s syndrome: state of the art. Lancet Diabetes Endocrinol 4(7), 611\u2013629 (2016). https:\/\/doi.org\/10.1016\/S2213-8587(16)00086-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3075_CR14","doi-asserted-by":"publisher","unstructured":"Cosentini, D., Lagan\u00e0, M., Turla, A., Tiberio, G.A.M., Grisanti, S., Berruti, A.: Letter to the editor from Berruti et al: \u201cCytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients\u2019 Survival\u201d. J Clin Endocrinol Metab.: dgac169 (2022). https:\/\/doi.org\/10.1210\/clinem\/dgac169","DOI":"10.1210\/clinem\/dgac169"},{"issue":"1","key":"3075_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","volume":"106","author":"NA Tritos","year":"2021","unstructured":"N.A. Tritos, Adrenally directed medical therapies for cushing syndrome. J Clin Endocrinol Metab 106(1), 16\u201325 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa778","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3075_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12020-017-1428-9","volume":"61","author":"M Claps","year":"2018","unstructured":"M. Claps, S. Cerri, S. Grisanti, B. Lazzari, V. Ferrari, E. Roca, P. Perotti, M. Terzolo, S. Sigala, A. Berruti, Adding metyrapone to chemotherapy plus mitotane for Cushing\u2019s syndrome due to advanced adrenocortical carcinoma. Endocrine 61(1), 169\u2013172 (2018). https:\/\/doi.org\/10.1007\/s12020-017-1428-9","journal-title":"Endocrine"},{"issue":"9","key":"3075_CR17","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","volume":"ume 96","author":"P Kamenick\u00fd","year":"2011","unstructured":"P. Kamenick\u00fd, C. Droumaguet, S. Salenave, A. Blanchard, C. Jublanc, J.F. Gautier, S. Brailly-Tabard, S. Leboulleux, M. Schlumberger, E. Baudin, P. Chanson, J. Young, Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing\u2019s Syndrome. J Clin Endocrinol Metab ume 96(9), 2796\u20132804 (2011). https:\/\/doi.org\/10.1210\/jc.2011-0536","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3075_CR18","doi-asserted-by":"publisher","first-page":"L7","DOI":"10.1530\/EJE-20-0557","volume":"183","author":"M Haissaguerre","year":"2020","unstructured":"M. Haissaguerre, M. Puerto, M.L. Nunes, A. Tabarin, Efficacy and tolerance of osilodrostat in patients with severe Cushing\u2019s syndrome due to non-pituitary cancers. Eur J Endocrinol 183(4), L7\u2013L9 (2020).","journal-title":"Eur J Endocrinol"},{"key":"3075_CR19","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.4158\/EP151104.CR","volume":"2","author":"M Claps","year":"2016","unstructured":"M. Claps, B. Lazzari, S. Grisanti, V. Ferrari, M. Terzolo, S. Sigala, S. Vezzoli, M. Memo, M. Castellano, A. Berruti, Management of severe cushing\u2019s syndrome induced by adrenocortical carcinoma with abiraterone acetate: a case report. AACE Clin Case Rep 2, e337\u2013e341 (2016). https:\/\/doi.org\/10.4158\/EP151104.CR","journal-title":"AACE Clin Case Rep"},{"issue":"12","key":"3075_CR20","doi-asserted-by":"publisher","first-page":"4594","DOI":"10.1210\/jc.2016-2414","volume":"101","author":"C Fiorentini","year":"2016","unstructured":"C. Fiorentini, M. Fragni, P. Perego, S. Vezzoli, S.A. Bonini, M. Tortoreto, D. Galli, M. Claps, G.A. Tiberio, M. Terzolo, C. Missale, M. Memo, G. Procopio, N. Zaffaroni, A. Berruti, S. Sigala, Antisecretive and antitumor activity of abiraterone acetate in human adrenocortical cancer: a preclinical study. J Clin Endocrinol Metab 101(12), 4594\u20134602 (2016). https:\/\/doi.org\/10.1210\/jc.2016-2414","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 5","key":"3075_CR21","doi-asserted-by":"publisher","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","volume":"27","author":"F Roila","year":"2016","unstructured":"F. Roila, A. Molassiotis, J. Herrstedt, M. Aapro, R.J. Gralla, E. Bruera, R.A. Clark-Snow, L.L. Dupuis, L.H. Einhorn, P. Feyer, P.J. Hesketh, K. Jordan, I. Olver, B.L. Rapoport, J. Roscoe, C.H. Ruhlmann, D. Walsh, D. Warr, M. van der Wetering, participants of the MASCC\/ESMO Consensus Conference Copenhagen 2015.: 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. Sep 27(suppl 5), v119\u2013v133 (2016). https:\/\/doi.org\/10.1093\/annonc\/mdw270","journal-title":"Ann Oncol. Sep"},{"issue":"2","key":"3075_CR22","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"S.R. Bornstein, B. Allolio, W. Arlt, A. Barthel, A. Don-Wauchope, G.D. Hammer, E.S. Husebye, D.P. Merke, M.H. Murad, C.A. Stratakis, D.J. Torpy, Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. Feb 101(2), 364\u2013389 (2016). https:\/\/doi.org\/10.1210\/jc.2015-1710","journal-title":"J Clin Endocrinol Metab. Feb"},{"issue":"8","key":"3075_CR23","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","volume":"88","author":"FE de Jongh","year":"2003","unstructured":"F.E. de Jongh, R.N. van Veen, S.J. Veltman, R. de Wit, M.E. van der Burg, M.J. van den Bent, A.S. Planting, W.J. Graveland, G. Stoter, J. Verweij, Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88(8), 1199\u20131206 (2003). https:\/\/doi.org\/10.1038\/sj.bjc.6600884","journal-title":"Br J Cancer"},{"issue":"1","key":"3075_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1007\/s10157-017-1448-z","volume":"22","author":"S Horie","year":"2018","unstructured":"S. Horie, M. Oya, M. Nangaku, Y. Yasuda, Y. Komatsu, M. Yanagita, Y. Kitagawa, H. Kuwano, H. Nishiyama, C. Ishioka, H. Takaishi, H. Shimodaira, A. Mogi, Y. Ando, K. Matsumoto, D. Kadowaki, S. Muto, Guidelines for treatment of renal injury during cancer chemotherapy 2016. Clin Exp Nephrol 22(1), 210\u2013244 (2018). https:\/\/doi.org\/10.1007\/s10157-017-1448-z","journal-title":"Clin Exp Nephrol"},{"issue":"7","key":"3075_CR25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s004670100610","volume":"16","author":"B Erdlenbruch","year":"2001","unstructured":"B. Erdlenbruch, A. Pekrum, C. Roth, R.W. Grunewald, W. Kern, M. Lakomek, Cisplatin nephrotoxicity in children after continuous 72-h and 3x1-h infusions. Pediatr Nephrol 16(7), 586\u2013593 (2001). https:\/\/doi.org\/10.1007\/s004670100610","journal-title":"Pediatr Nephrol"},{"key":"3075_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","volume":"135","author":"F Griesinger","year":"2019","unstructured":"F. Griesinger, E.E. Korol, S. Kayaniyil, N. Varol, T. Ebner, S.M. Goring, Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis. Lung Cancer 135, 196\u2013204 (2019). https:\/\/doi.org\/10.1016\/j.lungcan.2019.07.010","journal-title":"Lung Cancer"},{"issue":"2","key":"3075_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/sj.bjc.6603810","volume":"97","author":"H Okamoto","year":"2007","unstructured":"H. Okamoto, K. Watanabe, H. Kunikane, A. Yokoyama, S. Kudoh, T. Asakawa, T. Shibata, H. Kunitoh, T. Tamura, N. Saijo, Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 97(2), 162\u2013169 (2007). https:\/\/doi.org\/10.1038\/sj.bjc.6603810","journal-title":"Br J Cancer"},{"issue":"17","key":"3075_CR28","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djg036","volume":"95","author":"A du Bois","year":"2003","unstructured":"A. du Bois, H.J. L\u00fcck, W. Meier, H.P. Adams, V. M\u00f6bus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schr\u00f6der, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn, J. Pfisterer, Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie Ovarian Cancer Study Group.; A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95(17), 1320\u20131329 (2003). https:\/\/doi.org\/10.1093\/jnci\/djg036","journal-title":"J Natl Cancer Inst"},{"issue":"5 Suppl 12","key":"3075_CR29","first-page":"88","volume":"22","author":"DS Alberts","year":"1995","unstructured":"D.S. Alberts, Carboplatin versus cisplatin in ovarian cancer. Semin Oncol 22(5 Suppl 12), 88\u201390 (1995).","journal-title":"Semin Oncol"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03075-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T09:25:08Z","timestamp":1661419508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,14]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["3075"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03075-y","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,14]]},"assertion":[{"value":"2 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}